Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.22 USD

29.22
13,277,071

+0.25 (0.86%)

Updated Sep 27, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PFE vs. NVO: Which Stock Is the Better Value Option?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

Bayer Submits Application for Label Expansion of Prostate Cancer Drug

by Zacks Equity Research

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Rimmi Singhi headshot

4 High Earnings Yield Stocks That Value Investors Should Buy Now

by Rimmi Singhi

Unlock your portfolio value by investing in these high-earnings stocks like PPC, PFE, IAG and ASIX.

Nalak Das headshot

Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside

by Nalak Das

Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.

Pfizer (PFE) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.

MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study

by Zacks Equity Research

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.

Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market

by Zacks Equity Research

PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.

Kinjel Shah headshot

Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health

by Kinjel Shah

Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.

AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

by Zacks Equity Research

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Chevron & ServiceNow

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Chevron Corporation (CVX) and ServiceNow, Inc. (NOW), as well as two micro-cap stocks Sypris Solutions, Inc. (SYPR) and Mobile Infrastructure Corporation (BEEP).

Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time

by Zacks Equity Research

The higher settlement offer and a high percentage of claimant support may improve JNJ's chances of success after the previous two failures.

EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer

by Zacks Equity Research

If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

by Zacks Equity Research

The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech's updated version of mRNA COVID-19 jab, Comirnaty.

Here's Why Pfizer (PFE) Fell More Than Broader Market

by Zacks Equity Research

In the closing of the recent trading day, Pfizer (PFE) stood at $29.42, denoting a -0.83% change from the preceding trading day.

Roche Antiviral Drug Reduces Transmission in Late-stage Study

by Zacks Equity Research

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected person to household members.

Kinjel Shah headshot

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

by Kinjel Shah

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

by Zacks Equity Research

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?

by Zacks Equity Research

The upside comes after NUVL reported encouraging data on two experimental lung cancer therapies.

Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

by Zacks Equity Research

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%

by Zacks Equity Research

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Lilly Gets FDA Approval for Eczema Drug Ebglyss

by Zacks Equity Research

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

Andrew Rocco headshot

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

by Andrew Rocco

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

Nalak Das headshot

Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns

by Nalak Das

Three large-cap stocks ??? AES, PFE and UNM ??? currently offer attractive short-term returns along with a high dividend rate.

Rajani Lohia headshot

5 Bargain Price-to-Sales Stocks With High Growth Prospects

by Rajani Lohia

The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, BTU, HG, BBSI and PFE hold promise.